Viralgen’s Post

Did you know that Portugal has a rich biotech ecosystem that is rapidly growing? 🇵🇹 🚀 Biotech in the country now ranks fifth out of the 35 technological rankings regarding patent publications. 🔬 And, more than 80% of all patents published by Portuguese biotechnology companies took place in the last ten years, suggesting that the industry is on the rise. 📈 So, check out our latest article, as we take a look at seven healthcare-focused biotech companies leading the way in Portugal! 👇️ https://lnkd.in/dtF5E3mg #portugalbiotech #biotechecosystem #healthcareinnovation #biotechgrowth #biotechnews #medicalresearch #biotechtrends BSIM Therapeutics | Exogenus Therapeutics | IMMUNETHEP | LiMM Therapeutics | Luzitin SA | TechnoPhage, SA | P-BIO - Associação Portuguesa de Bioindústria | Health Cluster Portugal | Bionova Capital | iBET - Instituto de Biologia Experimental e Tecnológica | Fundação para a Ciência e a Tecnologia (FCT)

🔥 2seventy bio cierra un acuerdo con Novo Nordisk para vender su candidato para hemofilia A y su tecnología de edición genética por 40 millones de dólares 𝐃𝐞𝐭𝐚𝐥𝐥𝐞𝐬 𝐝𝐞𝐥 𝐚𝐜𝐮𝐞𝐫𝐝𝐨 🤝 2seventy bio ha vendido su candidato para hemofilia A y su tecnología de edición de genes in vivo MegaTAL a Novo Nordisk. 💰 2seventy bio recibirá hasta 40 millones de dólares, concluyendo un acuerdo de investigación para 2019. 👨🔬 Unos setenta miembros del equipo biológico se unirán a Novo Nordisk para continuar el desarrollo del programa. 𝐑𝐞𝐞𝐧𝐟𝐨𝐪𝐮𝐞 𝐝𝐞 𝐞𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐚 𝐝𝐞 2𝐬𝐞𝐯𝐞𝐧𝐭𝐲 𝐛𝐢𝐨 🎯 2seventy bio se centrará ahora en su terapia con células CAR-T dirigida a BCMA, Abecma, para el mieloma múltiple. 🌟 Abecma, desarrollado con Bristol Myers Squibb, recibió la aprobación de la FDA en abril de 2024. https://lnkd.in/dQ-BXqe3 #farmaceuticas #biopharma #pharma #acuerdo #innovacion #hemofilia

¿Buscas un #anticuerpo monoclonal para tu investigación? 👨🔬 👩💼 En Abyntek Biopharma contamos con un equipo científico-técnico con dilatada experiencia en el diseño de anticuerpos #monoclonales por técnicas de hibridoma o recombinantes. Te ayudaremos a diseñar el antígeno adaptando las fases al proyecto para optimizar el rendimiento de la producción:   ✅ Producción de hibridoma. ✅ Anticuerpos monoclonales modificados. ✅ Secuenciación de anticuerpos. ✅ Anticuerpos recombinantes. ✅ Mantenimiento de hibridomas. ✅ Humanización. ✅ Anticuerpos monoclonales en parejas. 👉 Descubre nuestro servicio para el diseño de anticuerpos monoclonales a medida https://lnkd.in/dgzm9CjC #Anticuerpos #Bioreactivos #Bioreagents #Biotech

We thrilled to officially announce the pioneering companies selected for the BIO-X Accelerate program! Congratulations to: 🌟 ArgusEye – Revolutionizing bioprocessing with advanced biosensors. 🌟 Rarity Bioscience – Pioneering precision cancer diagnostics. 🌟 Readily Diagnostics – Developing rapid and impactful diagnostic tests. 🌟 Phenaros Pharmaceuticals – Innovative drug development. 🌟 Strike Pharma AB – Taking precision medicine to a new level. “We are very pleased to welcome these five innovative companies to the BIO-X Accelerate program. Previous rounds have shown that our support has contributed to companies attracting significant investment and taking important steps forward in their development. With the new participants, we look forward to continuing to drive innovation in life science and health, and contribute to a sustainable and digital transformation." – Dajana I., Project Manager for the BIO-X Accelerate program at STUNS. BIO-X Accelerate was initiated in 2020 with the goal of facilitating the transition of small and medium-sized enterprises within the region’s life science sector from the early stages to a rapid phase of innovation and growth. The project aimed to enhance the competitiveness of these companies by generating innovative products that have high demand in the global healthcare market. The BIO-X Accelerate program will be in progress during 2024-2026 with these companies and the new theme “IMPACT”. Read the full press release👇 https://lnkd.in/dFN99UQV This project is funded by The European Regional Development Fund (ERDF) via Tillväxtverket. Thanks to our strategic and supporting partners: UIC - Uppsala Innovation Centre, Connect Sverige Region Uppsala, LEAD (Business Incubator), Inkubera, Create Business Incubator, Linköpings universitet, Uppsala universitet and Örebro universitet Holding. #Uppsala #Lifescience #Innovation

Poder dar respuesta a problemas inimaginables como devolverle la vista a ciegos de nacimiento o recuperar los suelos agotados por el uso intensivo agrícola fueron algunos de los propósitos con los que se presentó el programa Leaps by Bayer una apuesta enorme por lograr innovación disruptiva y que se verá en el futuro. Una apuesta por la innovación en ciencia

The #Mpox #Stock Rally Continues- Virax Biolabs Group (NASDAQ: VRAX) Sees Big Gains #stockstowatch #biotech #virus #mpoxemergency Investorideas.com- News that inspires big investing ideas investorideas.com) a go-to platform for big investing ideas, including biotech and pharma stocks reports on trading and news for Virax Biolabs Group Limited (NASDAQ: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases.

Exciting News in Kidney Disease Research 🌟 Today marks a significant step forward in the fight against kidney disease. Borealis Biosciences, a new biotech company launched by Novartis and Versant Ventures, has emerged from stealth mode with a remarkable $150 million in Series A funding. This venture builds upon the successful acquisition of Chinook Therapeutics by Novartis, showcasing a continued commitment to innovative renal therapies. Borealis boasts a talented team of 25, many of whom are key figures from Chinook's Vancouver-based research team. Their mission? To develop next-generation RNA medicines for kidney disease, utilizing recent advancements in patient stratification, genetically defined targets, and RNA chemistry. Alongside the Series A funds, Borealis has secured an additional $100 million from a licensing deal with Novartis, highlighting the Big Pharma's dedication to renal medicine and xRNA technology. Versant and Novartis aim to foster an environment that drives pioneering renal science and drug discovery. Given the progress Borealis is set to achieve, it's clear that the journey to groundbreaking kidney disease treatments is just beginning. #KidneyDisease #Biotech #RNA #Pharma #Innovation

No te pierdas este reportaje de la Revista Farmabiotec a Román Ortega Bianchi, nuestro Head of Business Development & Commercial Strategy por Alberto Carazo y Fidel Chaves. En esta ocasión, Román menciona nuestros objetivos de cara a disrumpir el área de biotecnología: "En base a los números que analizamos y según una investigación del Milken Institute, en la actualidad se están desarrollando más de 1.000 terapias celulares y génicas, y se espera que hasta el 2030 se aprueben en EE.UU. entre 50 y 75 terapias. Además, Grand View Research prevé que el mercado mundial de anticuerpos monoclonales registre una tasa de crecimiento anual compuesto del 11,04% de 2023 a 2030. Nuestra industria se enfrenta a un crecimiento sin precedentes y la biofabricación se convertirá en el mayor cuello de botella de la cadena de valor. Por eso necesitamos que la producción sea fácil, escalable, repetible y sostenible. Ahí es donde queremos entrar nosotros. Contamos con un ecosistema de 20 productos en desarrollo que se potencian por complementariedad y busca optimizar cada paso del bioproceso." Accedé a la entrevista completa en la Revista Farmabiotec páginas 54 - 55: https://lnkd.in/dFSVPtMC Contactanos para saber más sobre cómo estamos en camino de resolver los desafíos de las empresas biofarmacéuticas, las instituciones académicas y las start-ups en: info@stamm.bio --------------------------------------------------- Don't miss this interview from Farmabiotec Magazine to Román Ortega Bianchi, our Head of Business Development & Commercial Strategy by Alberto Carazo and Fidel Chaves. "Based on the numbers we analyzed and according to research from the Milken Institute, more than 1,000 cell and gene therapies are currently being developed, and it is expected that between 50 and 75 therapies will be approved in the US by 2030. Furthermore, Grand View Research forecasts the global monoclonal antibodies market to register a compound annual growth rate of 11.04% from 2023 to 2030. Our industry is facing unprecedented growth and biomanufacturing will become the biggest bottleneck of the value chain. That is why we need production to be easy, scalable, repeatable and sustainable. That is where we want to enter. We have an ecosystem of 20 products in development that are enhanced by complementarity and seek optimize each step of the bioprocess." Access the full interview in Farmabiotec Magazine pages 54 - 55: https://lnkd.in/dFSVPtMC Contact us to learn more about how we are on our way to solving the challenges of biopharmaceutical companies, academic institutions and start-ups at: info@stamm.bio

Single-Cell Multi-Omics Projected to Reach US$ 3377.5 Mn by 2030 | CAGR of 9.8% Experience the growth of the single-cell multi-omics market, projected to soar to US$ 337.75 Mn by 2030, with a remarkable CAGR of 9.8%. Embrace the future of genomics. #SingleCell #Genomics #FutureBioTech #MarketGrowth #MultiOmics #BiotechTrends #pharma #biotech #pharmiwebcom

Asabys Partners invierte en la belga Augustine Therapeutics de la mano de Eli lilly 💲 📈 Augustine Therapeutics, empresa biotecnológica pionera en el desarrollo de nuevas moléculas para el tratamiento de enfermedades neurodegenerativas y cardiometabólicas, anuncia que ha recaudado 17 millones de euros en el primer cierre de una #RondadeFinanciación Serie A liderada por Asabys Partners desde su fondo Sabadell Asabys II. La ronda ha contado también con la participación de la farmacéutica Eli Lilly & Company y la Fundación de Investigación Charcot-Marie-Tooth (CMT) con sede en EE.UU., así como con la participación de inversores ya existentes en la compañía, AdBio Partners, V-Bio Ventures, PMV, VIB New Ventures y Gemma Frisius Fund, el brazo de capital riesgo de KU Leuven. #Farmabiotec #Noticias #RondaFinanciación ➡ https://lnkd.in/dqmEn7mS